Table 2.
Spearman analysis between serum Cat-S, CysC and clinical parameters (n=200).
| Projects | Cat-S | CysC | ||
|---|---|---|---|---|
| r | P Value | r | P Value | |
| UACR (mg/g) | 0.76 | < 0.001 | 0.604 | < 0.001 |
| eGFR mL/min/(1.73 m2) | -0.54 | < 0.001 | -0.779 | < 0.001 |
| RBP (mg/L) | 0.38 | < 0.001 | 0.610 | < 0.001 |
| BUN (mmol/L) | 0.40 | < 0.001 | 0.609 | < 0.001 |
| Scr (μmol/L) | 0.53 | < 0.001 | 0.749 | < 0.001 |
| FBG (mmol/L) | -0.08 | 0.28 | -0.127 | 0.074 |
| TC (mmol/L) | 0.14 | 0.04 | 0.108 | 0.126 |
| TG (mmol/L) | 0.12 | 0.09 | 0.216 | 0.002 |
| LDL-C (mmol/L) | 0.07 | 0.35 | 0.076 | 0.282 |
| HDL-C (mmol/L) | -0.08 | 0.27 | -0.159 | 0.025 |
| SUA (μmol/L) | 0.25 | < 0.001 | 0.451 | < 0.001 |
| Cat-S (pg/mL) | – | – | 0.548 | < 0.001 |
| CysC (mg/L) | 0.548 | < 0.001 | – | – |